Stimuvax Phase 1/2 survival data support prior results



    BELLEVUE, WA, June 2 /CNW/ - Oncothyreon Inc. (Nasdaq:   ONTY) (TSX: ONY)
today announced the presentation of two-year survival data from a Phase 1/2
multicenter study of Stimuvax(R) (BLP25 liposomal vaccine) in patients (n=22)
with unresectable stage III non-small cell lung cancer. After a median
follow-up period of 26.7 months, the two-year overall survival rate was 64
percent (95 percent confidence interval, 44-84 percent). The data were
presented by Dr. N. R. Murray, British Columbia Cancer Agency, Fraser Valley
Center, Surrey, British Columbia, Canada, at the American Society of Clinical
Oncology Annual Meeting in Chicago on June 1, 2008.
    "The two-year overall survival data in the current study are similar to
the overall survival seen in a similar cohort of patients in Oncothyreon's
prior Phase 2b trial of Stimuvax," said Robert L. Kirkman, M.D., President and
CEO of Oncothyreon. "In that prior study, the two-year overall survival in
patients with Stage IIIb loco-regional disease was 57 percent in those treated
with Stimuvax plus best supportive care compared with 33 percent in those who
received best supportive care alone. We are very encouraged that the new data,
obtained in the same patient population and with the same formulation of
Stimuvax being used in the ongoing Phase 3 trial, are supportive of our prior
results."
    The Phase 1/2 trial was designed to evaluate the safety of Stimuvax
following a change in the manufacturer of the adjuvant component of the
vaccine. No new safety concerns were identified in the study. The trial was
completed by Merck KGaA of Darmstadt, Germany, which assumed responsibility
for the clinical development of Stimuvax in 2007.
    Merck KGaA currently is conducting a global Phase 3 trial of Stimuvax
known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a
randomized, double-blind, placebo-controlled study that will evaluate patients
with documented unresectable stage III NSCLC who have had a response or stable
disease after at least two cycles of platinum based chemo-radiotherapy. The
Phase 3 trial is expected to enroll more than 1,300 patients in approximately
30 countries. For more information on the START trial, or to find a
participating center and eligibility criteria, log on to www.nsclcstudy.com or
www.clinicaltrials.gov.

    About Stimuvax

    Stimuvax is an investigational therapeutic cancer vaccine designed to
induce an immune response to cancer cells that express MUC1, a glycoprotein
antigen widely expressed on common cancers. MUC1 is over expressed on many
cancers such as lung cancer, breast cancer, prostate cancer and colorectal
cancer. Stimuvax is thought to work by stimulating the body's immune system to
identify and destroy cancer cells expressing MUC1.

    About Oncothyreon

    Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information visit www.oncothyreon.com.

    Forward-Looking Statements

    In order to provide Oncothyreon's investors with an understanding of its
current intentions and future prospects, this release contains statements that
are forward looking, including statements related to payments Oncothyreon may
expect to receive; the therapeutic and commercial potential of Stimuvax;
future clinical development plans; the details of clinical trials; and the
anticipated future size of the market for Stimuvax. These forward-looking
statements represent Oncothyreon's intentions, plans, expectations and beliefs
and are based on its management's experience and assessment of historical and
future trends and the application of key assumptions relating to future events
and circumstances.
    Forward-looking statements involve risks and uncertainties, including
risks and uncertainties related to Oncothyreon's business and the general
economic environment. Many of these risks and uncertainties are beyond
Oncothyreon's control. These risks, uncertainties and other factors could
cause our actual results to differ materially from those projected in
forward-looking statements. Risks, uncertainties, and assumptions include
those predicting the timing, duration and results of clinical trials, the
timing and results of regulatory reviews, the safety and efficacy of Stimuvax,
and the possibility of future milestone and royalty payments. There can be no
guarantee that the results of earlier trials will be predictive of either
safety or efficacy in future trials. These and other risks and uncertainties
are described in the reports and other documents filed by Oncothyreon Inc.
with the SEC and/or Canadian regulatory authorities.
    Although Oncothyreon believes that any forward-looking statements
contained herein are reasonable, it can give no assurance that its
expectations are correct. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. For a detailed
description of the risks and uncertainties associated with Oncothyreon, you
are encouraged to review the official corporate documents filed by Oncothyreon
Inc. with the securities regulators in United States and Canada with the SEC
and on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims
any such obligation to) update or alter its forward-looking statements whether
as a result of new information, future events, or otherwise.

    Additional Information

    Additional information relating to Oncothyreon can be found on U.S. EDGAR
at www.sec.gov and on SEDAR at www.sedar.com.





For further information:

For further information: Investor and Media Relations Contact: Julie
Rathbun, Rathbun Communications, (206) 769-9219, ir@oncothyreon.com

Organization Profile

ONCOTHYREON INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890